Cargando…

Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists Using 3D-QSAR and Molecular Docking

Type 2 diabetes is becoming a global pandemic disease. As an important target for the generation and development of diabetes mellitus, peroxisome proliferator-activated receptor γ (PPARγ) has been widely studied. PPARγ agonists have been designed as potential anti-diabetic agents. The advanced devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jian, Yaning, He, Yuyu, Yang, Jingjing, Han, Wei, Zhai, Xifeng, Zhao, Ye, Li, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855852/ https://www.ncbi.nlm.nih.gov/pubmed/29473866 http://dx.doi.org/10.3390/ijms19020630

Ejemplares similares

Role of peroxisome proliferator‐activated receptor gamma agonist in improving hepatic steatosis: Possible molecular mechanism
por: Park, Cheol‐Young, et al.
Publicado: (2012)

Benzoxazinones as Human Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Agonists: A Docking Study Using Glide
por: Das, N., et al.
Publicado: (2011)

Design and Screening of New Lead Compounds for Autism Based on QSAR Model and Molecular Docking Studies
por: Chen, Yongjian, et al.
Publicado: (2022)

QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease
por: Song, Fucheng, et al.
Publicado: (2023)

QSAR, Docking, and Molecular Dynamics Simulation Studies of Sigmacidins as Antimicrobials against Streptococci
por: Ye, Jiqing, et al.
Publicado: (2022)

Molecular Recognition of Agonist and Antagonist for Peroxisome Proliferator-Activated Receptor-α Studied by Molecular Dynamics Simulations
por: Liu, Mengyuan, et al.
Publicado: (2014)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists
por: El-Zahabi, Mohamed Ayman, et al.
Publicado: (2022)

Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022)

Molecular docking of Glyceroneogenesis pathway intermediates with Peroxisome Proliferator- Activated Receptor-Alpha (PPAR-α)
por: Subramani, Parasuraman Aiya, et al.
Publicado: (2013)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

A Role for Peroxisome Proliferator-Activated Receptor Gamma Agonists in Counteracting the Degeneration of Cardiovascular Grafts
por: Assmann, Anna Kathrin, et al.
Publicado: (2022)

Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization
por: Kumar, Rajnish, et al.
Publicado: (2016)

Polyacetylenes from Notopterygium incisum–New Selective Partial Agonists of Peroxisome Proliferator-Activated Receptor-Gamma
por: Atanasov, Atanas G., et al.
Publicado: (2013)

Identification of Isosilybin A from Milk Thistle Seeds as an Agonist of Peroxisome Proliferator-Activated Receptor Gamma
por: Pferschy-Wenzig, Eva-Maria, et al.
Publicado: (2014)

Polyyne Hybrid Compounds from Notopterygium incisum with Peroxisome Proliferator-Activated Receptor Gamma Agonistic Effects
por: Liu, Xin, et al.
Publicado: (2014)

Lipoxygenase Inhibition Activity of Coumarin Derivatives—QSAR and Molecular Docking Study
por: Lončarić, Melita, et al.
Publicado: (2020)

Melatonin and Its Metabolites Can Serve as Agonists on the Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor Gamma
por: Slominski, Andrzej T., et al.
Publicado: (2023)

Combined 3D-QSAR, molecular docking and dynamics simulations studies to model and design TTK inhibitors
por: Ashraf, Noureen, et al.
Publicado: (2022)

Molecular mechanism of benign biliary stricture inhibition by rosiglitazone-activated peroxisome proliferator-activated receptor gamma
por: Jiamei, Lu, et al.
Publicado: (2022)

3D-QSAR Study of Combretastatin A-4 Analogs Based on Molecular Docking
por: Jin, Yinghua, et al.
Publicado: (2011)

Searching glycolate oxidase inhibitors based on QSAR, molecular docking, and molecular dynamic simulation approaches
por: Cabrera, Nicolás, et al.
Publicado: (2022)

Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model
por: Mahal, Amandeep, et al.
Publicado: (2018)

Effects of Peroxisome Proliferator-Activated Receptor-Gamma Agonists on Cognitive Function: A Systematic Review and Meta-Analysis
por: Zhong, Hongfei, et al.
Publicado: (2023)

Biological enrichment prediction of polychlorinated biphenyls and novel molecular design based on 3D-QSAR/HQSAR associated with molecule docking
por: Yang, Jiawen, et al.
Publicado: (2019)

Probing the origins of human acetylcholinesterase inhibition via QSAR modeling and molecular docking
por: Simeon, Saw, et al.
Publicado: (2016)

Molecular docking, QSAR and ADMET studies of withanolide analogs against breast cancer
por: Yadav, Dharmendra K, et al.
Publicado: (2017)

Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study
por: Márquez, Edgar, et al.
Publicado: (2019)

Recent Developments in 3D QSAR and Molecular Docking Studies of Organic and Nanostructures
por: Rasulev, Bakhtiyor
Publicado: (2016)

Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression
por: Burrage, Peter S, et al.
Publicado: (2008)

Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors
por: Liu, Genyan, et al.
Publicado: (2018)

Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies
por: Bhujbal, Swapnil P., et al.
Publicado: (2022)

Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation
por: Omeragic, Amila, et al.
Publicado: (2017)

3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors
por: Zuo, Ke, et al.
Publicado: (2017)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

Peroxisome Proliferator-Activated Receptor-Gamma Agonists Suppress Tissue Factor Overexpression in Rat Balloon Injury Model with Paclitaxel Infusion
por: Park, Jun-Bean, et al.
Publicado: (2011)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis
por: Tomita, Tetsuya, et al.
Publicado: (2006)

Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
por: Khan, Mahmood Ahmad, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor-gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model
por: Omeragic, Amila, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c3rlmdh6eaq6m44aqpsv0jtm5v